Leica Novocastra™ Immunohistochemistry Antibody (Hematologic Disorder and Blood Cancer Markers)
Singapore·CLASS B IVD·Leica Biosystems Newcastle Ltd·Registered June 27, 2024- Device Class
- CLASS B IVD
- Medical Speciality Area
- Immunology
- Registration Number
- DE0509465
- Registration Date
- June 27, 2024
- Retention Due Date
- June 26, 2025
- Short Name
- Leica
- Address
- Balliol Business Park, Benton Lane, Newcastle upon Tyne, NE12 8EW, UNITED KINGDOM
- Address
- 15 TUKANG INNOVATION DRIVE, SINGAPORE 618299
- Address
- 18 BOON LAY WAY, TRADEHUB 21, #05-105, SINGAPORE 609966 15 TUKANG INNOVATION DRIVE, SINGAPORE 618299
- Model Name(s)
- Novocastra p80 (Anaplastic Lymphoma Kinase) Novocastra CD4 Novocastra CD56 (NCAM) Novocastra CD8 Novocastra Multiple Myeloma Oncogene 1 (MUM-1)
- Model Identifier(s)
- NCL-L-ALK NCL-L-CD4-368 NCL-L-CD56-504 NCL-L-CD8-4B11 NCL-L-MUM1
Access comprehensive regulatory information for Leica Novocastra™ Immunohistochemistry Antibody (Hematologic Disorder and Blood Cancer Markers) in the Singapore medical device market through Pure Global AI's free database. This CLASS B IVD medical device is registered under HSA registration number DE0509465 and owned by Leica Biosystems Newcastle Ltd. The device was registered on June 27, 2024.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.